The Drug And Pace Health cliNical Evaluation (DAPHNE) study: A randomized trial comparing sotalol versus β-blockers to treat symptomatic atrial fibrillation in patients with brady-tachycardia syndrome implanted with an antitachycardia pacemaker

American Heart Journal

Volumn 156, Issue 2, 2008, Pages 373.e1-373.e8

  Capucci, Alessandro ^a,j   Botto, GianLuca ^b,j   Molon, Giulio ^c,j   Spampinato, Andrea ^d,j   Favale, Stefano ^e,j   Proclemer, Alessandro ^f,j   Porfilio, Antonio ^g,j   Marotta, Tiziana ^h,j   Vimercati, Marco ^h,j   Boriani, Giuseppe ^i,j  

^a Civile Hospital   (Italy)

^b SANT ANNA HOSPITAL   (Italy)

^c S Cuore Hospital   (Italy)

^d Cardiology Department   (Italy)

^e UNIVERSITY OF BARI   (Italy)

^f SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^g FATEBENEFRATELLI HOSPITAL   (Italy)

^h Medtronic Italia   (Italy)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL; SOTALOL;

AGED; ARTICLE; ARTIFICIAL HEART PACEMAKER; BRADYCARDIA; CARDIAC PATIENT; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEVICE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; HEART ATRIUM FIBRILLATION; HEART PACING; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SINGLE BLIND PROCEDURE; TACHYCARDIA;

EID: 47849094379     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.01.032     Document Type: Article

References (31)

1. AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 42 (2003) 20-29
2. Gregoratos G., Abrams J., and Epstein A.E. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices. Circulation 106 (2002) 2145-2161
3. Savelieva I., and Camm A.J. The results of pacing trials for the prevention and termination of atrial tachyarrhythmias: is there any evidence of therapeutic breakthrough?. J Interv Card Electrophysiol 8 (2003) 103-115
4. Disertori M., Padeletti L., and Santini M. Antitachycardia pacing therapies to terminate atrial tachyarrhythmias: the AT500 Italian Registry. Eur Heart J Suppl 3 (2001) P16-P24
5. Boriani G., Padeletti L., and Santini M. Predictors of atrial antitachycardia pacing efficacy in patients affected by brady-tachy form of sick sinus syndrome and implanted with a DDDRP device. J Cardiovasc Electrophysiol 16 (2005) 714-723
6. Gillis A.M., Koehler J., and Morck M. High atrial antitachycardia pacing therapy efficacy is associated with a reduction in atrial tachyarrhythmia burden in a subset of patients with sinus node dysfunction and paroxysmal atrial fibrillation. Heart Rhythm 2 (2005) 791-796
7. Lee M.A., Weachter R., Pollak S., et al. The effect of atrial pacing therapies on atrial tachyarrhythmia burden and frequency: results of a randomized trial in patients with bradycardia and atrial tachyarrhythmias. J Am Coll Cardiol 41 (2003) 1926-1932
8. Padeletti L., Purerfellner H., and Adler S.W. Combined efficacy of atrial septal lead placement and atrial pacing algorithms for prevention of paroxysmal atrial tachyarrhythmia. J Cardiovasc Electrophysiol 14 (2003) 1189-1195
9. Israel C.W., Gronefeld G., and Ehrlich J.R. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol 43 (2004) 47-52
10. Carlson M.D., Ip J., Messenger J., et al. A new pacemaker algorithm for the treatment of atrial fibrillation: results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT). J Am Coll Cardiol 42 (2003) 627-633
11. Levy S., Breithardt G., and Campbell R.W. Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J 19 (1998) 1294-1320
12. Capucci A., Villani G.Q., and Marrazzo N. The complementary role of drug, ablation and device in the electrical therapy of atrial fibrillation. Eur Heart J Suppl 3 (2001) P47-P52
13. Camm A.J., and Savelieva I. Rationale and patient selection for "hybrid" drug and device therapy in atrial and ventricular arrhythmias. J Interv Card Electrophysiol 9 (2003) 207-214
14. Saksena S., and Madan N. Hybrid therapy of atrial fibrillation: algorithms and outcome. J Interv Card Electrophysiol 9 (2003) 235-247
15. Naccarelli G.V., Wolbrette D.L., and Khan M. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol 91 (2003) 15D-26D
16. Naccarelli G.V., Wolbrette D.L., and Bhatta L. A review of clinical trials assessing the efficacy and safety of newer antiarrhythmic drugs in atrial fibrillation. J Interv Card Electrophysiol 9 (2003) 215-222
17. McNamara R.L., Tamariz L.J., and Segal J.B. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 139 (2003) 1018-1033
18. Plewan A., Lehmann G., and Ndrepepa G. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. Eur Heart J 22 (2001) 1504-1510
19. Reiffel J.A. Drug choices in the treatment of atrial fibrillation. Am J Cardiol 85 (2000) 12D-19D
20. Andrews T.C., Reimold S.C., and Berlin J.A. Prevention of supraventricular arrhythmias after coronary artery bypass surgery. A meta-analysis of randomized control trials. Circulation 84 5 Suppl (1991) III236-III244
21. Steeds R.P., Birchall A.S., and Smith M. An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. Heart 82 (1999) 170-175
22. Workman A.J., Kane K.A., and Russell J.A. Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: evidence of pharmacological remodelling. Cardiovasc Res 58 (2003) 518-525
23. Benditt D., Williams J.H., and Jin J. l-Sotalol atrial fibrillation/flutter study group. Am J Cardio 84 (1999) 270-277
24. Haverkamp W., Hordt M., and Breithardt G. Torsade de pointes secondary to d,l-sotalol after catheter ablation of incessant atrioventricular reentrant tachycardia-evidence for a significant contribution of the "cardiac memory". Clin Cardiol 21 (1998) 55-58
25. Israel C.W., Ehrlich J.R., and Gronefeld G. Prevalence, characteristics and clinical implications of regular atrial tachyarrhythmias in patients with atrial fibrillation: insights from a study using a new implantable device. J Am Coll Cardiol 38 (2001) 355-363
26. Israel C.W., Hugl B., and Unterberg C. AT500 Verification Study Investigators. Pace-termination and pacing for prevention of atrial tachyarrhythmias: results from a multicenter study with an implantable device for atrial therapy. J Cardiovasc Electrophysiol 12 (2001) 1121-1128
27. Wilkoff B.L., Kuhlkamp V., and Volosin K. Critical analysis of dual-chamber implantable cardioverter-defibrillator arrhythmia detection: results and technical considerations. Circulation 103 (2001) 381-386
28. Jenkins L.S., Brodsky M., and Schron E. Quality of life in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 149 (2005) 112-120
29. Fuster V., Rydén L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation. Circulation 114 (2006) e257-e354
30. Ricci R., Santini M., and Padeletti L. Atrial tachyarrhythmia recurrence temporal patterns in bradycardia patients implanted with antitachycardia pacemakers. J Cardiovasc Electrophysiol 15 (2004) 44-51
31. Padeletti L., Santini M., and Boriani G. Temporal variability of atrial tachyarrhythmia burden in bradycardia-tachycardia syndrome patients. Eur Heart J 26 (2005) 165-172